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A B S T R A C T
Achromobacter xylosoxidans, a gram-negative bacillus with low virulence has rarely been reported to cause clinically signiﬁcant infections. We report an unusual case
of MDR Achromobacter xylosoxidans/denitriﬁcans bacteremia from a peripherally inserted central catheter (PICC) and subsequent fatal pleural empyema due to MDR
Escherichia coli and Streptococcus anginosus. A 44-year-old male presented to the hospital with chief complaints of chest tightness associated with a productive cough.
He was found to have pleural empyema secondary to MDR E. coli and S. anginous. Three months prior to current presentation, he had a history of MDR A.
xylosoxidans originating from a PICC. The patient expired even after appropriate management. Thoracic empyema continues to cause signiﬁcant morbidity and
mortality despite the improvement of antimicrobial therapy and the existence of multiple options for drainage of the infected pleural space. The bacteriology of
thoracic empyema has been changing since the introduction of antibiotics. Typical antibiotics used to treat these MDR pathogens have become obsolete. Therefore,
physicians should be aggressive in their diagnostic approach to pleural empyema, since the isolation of MDR aerobic gram-negative bacilli or multiple pathogens
from the pleural ﬂuid is associated with a poor prognosis and indicates a need for more aggressive antimicrobial chemotherapy. Also, the association of indwelling
medical devices and MDR Achromobacter bacteremia should be known.
1. Introduction
Achromobacter xylosoxidans (A. xylosoxidans) is a low virulence
gram-negative bacillus recently emerging as a causative agent of in-
fection in both immunocompromised and immunocompetent popula-
tions [ [1,2]]. Multi Drug Resistant (MDR) A. xylosoxidans has rarely
been reported to cause clinically signiﬁcant infections. We report an
unusual case of MDR Achromobacter xylosoxidans/denitriﬁcans bacter-
emia from a peripherally inserted central catheter (PICC) and sub-
sequent fatal pleural empyema due to MDR Escherichia coli (E. coli) and
Streptococcus anginosus (S. anginosus).
2. Case presentation
A 44-year-old male presented to the hospital with chief complaints
of right foot pain, swelling and inability to ambulate. Medical history
was signiﬁcant for type 2 diabetes mellitus, diabetic foot ulcer, and
osteomyelitis of right foot status post intravenous antibiotics through a
peripherally inserted central catheter (PICC). On physical examination,
the patient was noted to have bilateral lower extremity edema and a
right foot plantar ulcer associated with erythema and warmth.
Magnetic Resonance Imaging of right foot showed hallux
Metatarsophalangeal (MTP) plantar soft tissue ulcer with gas locules at
hallux MTP joint associated with Hallux metatarsal/proximal pha-
langeal osteomyelitis with septic arthritis. The patient underwent a
right foot partial ﬁrst ray amputation. Also, a Computed Tomography of
chest obtained for shortness of breath revealed an incidental segmental
and subsegmental bilateral upper lobe pulmonary emboli and a right
upper lobe wedge-shaped peripheral ground glass and cavitary opa-
cities consistent with pulmonary infarcts.
Cultures were obtained from peripheral blood and PICC line. Both
grew Achromobacter xylosoxidans/denitriﬁcans which was resistant to
meropenem, cefepime, piperacillin/tazobactam aztreonam, gentamicin,
and tobramycin and sensitive to ciproﬂoxacin, levoﬂoxacin, and
Bactrim. A. xylosoxidans was considered MDR and the PICC was con-
sidered the primary source of bacteremia. Repeat blood cultures after
three days of empiric antibiotic therapy were negative. The PICC was
removed and a new PICC was placed and the patient was subsequently
discharged on intravenous ciproﬂoxacin and vancomycin for six weeks.
Also, a transesophageal echocardiogram was negative for vegetation
and endocarditis was ruled out.
Three months later, the patient was readmitted for chest tightness
associated with a productive cough and nausea which were present for
four days prior to presentation. On physical examination, the patient
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was noted to have right sided crackles, bilateral lower extremity edema,
and a right foot plantar ulcer. The patient was tachycardic with a heart
rate of 112 and afebrile. Laboratory studies revealed an elevated leu-
kocyte count of 17 k/ul with a neutrophil predominance of 79% and
low hemoglobin of 8.5 g/dL. He had normal electrolytes, normal kidney
function and normal liver enzymes. Initial imaging with chest x-ray
showed right lung opacity with lower lobe predominance. On further
imaging with a Computed Tomography of the chest revealed no evi-
dence of PE and showed right lower lobe consolidation with small right
pleural eﬀusion, right upper lobe consolidation with partial ground
glass opacity and a right upper lobe cavitary lesion measuring 3.5× 2
cm. The eﬀusion and consolidations were new whereas the cavitary
lesion was thought to be secondary to ischemic necrosis of previous
pulmonary infarction at the same location.
A diagnostic thoracentesis was done which showed turbid ﬂuid with
a total nucleated cell count of 36034/μL with 67% segmented granu-
locytes and many bacteria seen on gram stain. The Pleural ﬂuid cultures
grew E. coli which was resistant to ampicillin, gentamicin, levoﬂoxacin,
and ciproﬂoxacin and sensitive to ceftriaxone, Bactrim, aztreonam,
cefepime, meropenem, imipenem, piperacillin/tazobactam and S. an-
ginosus which was pan-sensitive to ceftriaxone, clindamycin, vanco-
mycin, levoﬂoxacin, erythromycin. E. coli was considered MDR and the
patient was started on intravenous zosyn and a video-assisted thor-
acoscopic surgery with decortication was done for right pleural em-
pyema. The patient's clinical condition was initially improving but after
an extensive hospital stay he subsequently died after a cardiac arrest
(see Figs. 1–3).
3. Discussion
Achromobacter xylosoxidans (previously termed Alcaligenes
Xylosoxidans) was ﬁrst described by Yabuuchi and Ohyama in 1971
after it was isolated from the ear discharge of patients with chronic
otitis media [2]. A. xylosoxidans is a ﬂagellated, motile, aerobic, gram-
negative bacillus that is a non-glucose fermenter. The genus Achro-
mobacter has multiple species: xylosoxidans, ruhlandii, piechaudii,
denitriﬁcans, spanius, insolitus, and marplatensis. Clinically signiﬁcant
species are xylosoxidans and denitriﬁcans [1]. They are diﬃcult to
identify and separate by phenotype and even by 16S rRNA gene se-
quence, and vernaculars such as 'Achomobacter spp.' or 'Achomobacter
xylosoxidans/denitriﬁcans' are widely used. In immunocompromised
hosts, nosocomial infections like endocarditis, urinary tract infections,
and pneumonia, caused by A. xylosoxidans have been observed [3].
Case mortality ranging from 3% for bacteremia with up to 80% for
neonatal infection has been previously described for A. xylosoxidans
nosocomial infections [2]. A. xylosoxidans pneumonia has a high case
fatality rate of 67% [4]. Pulmonary involvement by A. xylosoxidans has
been seen in cystic ﬁbrosis patients. A. xylosoxidans pneumonia has
been reported in patients with underlying malignancy, patients with
IgM deﬁciency and those on mechanical ventilation [2]. Rare
complications like empyema, adult respiratory distress syndrome,
chronic scarring, secondary and recurrent pneumonia have been re-
ported [4].
Treatment of A. xylosoxidans is usually diﬃcult due to drug re-
sistance [2]. Achromobacter species isolates have been found to be
resistant to ﬁrst and second-generation cephalosporin, aminoglycosides
and narrow spectrum penicillins. They are usually susceptible to sul-
fonamides, carbapenems, and broad-spectrum penicillins third-genera-
tion cephalosporins; and variably susceptible to ﬂuoroquinolones [4].
However, in our case it was found to be MDR and was only sensitive to
ciproﬂoxacin, levoﬂoxacin and Bactrim. An organism is considered
MDR when an isolate is non-susceptible to at least one agent in three or
more antibiotic classes. Adjustment of antibiotic therapy should be
performed according to antibiotic susceptibility testing [3]. The prog-
nosis is generally excellent with clearance of the infection [1]. Duration
of treatment is not exactly deﬁned due to lack in speciﬁc guidelines [1].
Thoracic empyema continues to cause signiﬁcant morbidity and
mortality despite the improvement of antimicrobial therapy and the
existence of multiple options for drainage of the infected pleural space.
These infections can be diagnostically challenging and usually need a
sophisticated multidisciplinary management strategy [5]. The bacter-
iology of thoracic empyema has been changing since the introduction of
antibiotics. Before the antibiotic era, Streptococcus pneumoniae or B-
hemolytic streptococci were isolated in most empyema ﬂuid, and Sta-
phylococcus aureus was the most common pathogen of thoracic em-
pyema from 1955 to 1965. Over the past 30 years, aerobic gram-posi-
tive organisms have been the most frequent isolates in acute thoracic
empyema. Staphylococcus aureus and Streptococcus pneumonia ac-
counted for approximately 70% of all aerobic gram-positive isolates.
However, MDR gram-negative organisms were seen mostly in im-
munocompromised hosts, especially those with diabetes mellitus, ma-
lignancy and those with other MDR risk factors [6].
S. anginosus group previously referred to as Streptococci milleri
group are catalase negative, facultative anaerobes and includes three
taxonomically distinct species: S. anginosus, Streptococcus intermedius
and Streptococcus constellatus. They tend to form abscesses and em-
pyema thoracis which is their unique characteristic [7]. E. coli is a
Gram-negative bacillus and a facultative anaerobe. Cases of pneumonia
due to E. coli are uncommon and are usually hospital-acquired, ac-
counting for 9% of cases reported [8]. In our patient, the subsequent
MDR E. coli could possibly be attributed to impaired immunity.
The three phases of empyema, exudative (stage I), ﬁbrinopurulent
(stage II), and organizing (stage III) represent a continuously evolving
process that can be arrested by therapeutic intervention. The Stage I
empyema is usually treated with antibiotics and thoracocentesis or
chest tube drainage. Stage II disease is treated usually with ﬁbrinolytic
therapy or video-assisted thoracoscopic debridement. For Stage III
empyema, decortication is required. Early and aggressive management
of empyema provides rapid relief from sepsis and may shorten the
hospital stay [9]. The development of antimicrobial resistance among
Fig. 1. Initial axial Computed Tomography of the chest showing a right upper lobe wedge-shaped peripheral ground glass and cavitary opacities consistent with
pulmonary infarcts.
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gram-negative pathogens has been progressive and persistent. Classic
agents used to treat these pathogens have become obsolete. Of the few
new drugs available, many have already become targets for bacterial
mechanisms of resistance. MDR should be managed with the assistance
of an expert in the treatment of such infections. Treatment options are
currently limited. The antimicrobial stewardship and infection control
policies contribute signiﬁcantly against the worldwide emergence and
spread of MDR pathogens [10].
In conclusion, our case is unique as infection with one rare MDR
organism led to a fatal infection with another MDR organism. An oc-
currence like this has never been reported in medical literature to the
best of our knowledge. Firstly, physicians should be aware of the as-
sociation of PICC and Achromobacter bacteremia. Secondly, physicians
should pay more attention to pleural empyema and its microbiologic
etiology since the isolation of MDR aerobic gram-negative bacilli or
multiple pathogens from the pleural ﬂuid is associated with a poor
prognosis and indicates a need for more aggressive antimicrobial che-
motherapy.
Disclosure statement
No potential conﬂict of interest was reported by the authors. No
funding was received.
References
[1] H. Awadh, M. Mansour, O. Aqtash, Y. Shweihat, Pneumonia due to a rare pathogen,
Case Rep Infect Dis 2017 (2017) 3969682.
[2] S.S. Karanth, A. Gupta, M. Prabhu, Community acquired bilateral upper lobe
pneumonia with acute adrenal insuﬃciency: a new face of achromobacter xylo-
soxidans, Australas. Med. J. 5 (10) (2012) 531–533.
[3] E. Pérez Barragán, J. Sandino Pérez, L. Corbella, M.A. Orellana, M. Fernández-Ruiz,
Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a
10-year case series, Rev. Española Quimioter. 31 (3) (2018) 268–273.
[4] S. Aundhakar, M. Mane, A. Bharadiya, S. Pawar, Watch out! Pneumonia secondary
to achromobacter denitriﬁcans, Ann. Med. Health Sci. Res. 4 (Suppl 1) (2014)
S22–S24.
[5] T.H. Tsai, J.S. Jerng, K.Y. Chen, C.J. Yu, P.C. Yang, Community-acquired thoracic
empyema in older people, J. Am. Geriatr. Soc. 53 (7) (2005) 1203–1209.
[6] K.Y. Chen, P.R. Hsueh, Y.S. Liaw, P.C. Yang, K.T. Luh, A 10-year experience with
bacteriology of acute thoracic empyema: emphasis on Klebsiella pneumoniae in
patients with diabetes mellitus, Chest 117 (6) (2000) 1685–1689.
[7] S. Noguchi, K. Yatera, T. Kawanami, et al., The clinical features of respiratory in-
fections caused by the Streptococcus anginosus group, BMC Pulm. Med. 15 (2015)
133.
[8] F.Y. khan, Escherichia coli pleural empyema: two case reports and literature review,
Ann. Trop. Med. Public Health 4 (2011) 128–132.
[9] B.C. Tong, J. Hanna, E.M. Toloza, et al., Outcomes of video-assisted thoracoscopic
decortication, Ann. Thorac. Surg. 89 (1) (2010) 220–225.
[10] S.S. Kanj, Z.A. Kanafani, Current concepts in antimicrobial therapy against resistant
gram-negative organisms: extended-spectrum beta-lactamase-producing
Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-re-
sistant Pseudomonas aeruginosa, Mayo Clin. Proc. 86 (3) (2011) 250–259.
Fig. 2. Initial coronal Computed Tomography of the chest showing a right upper lobe wedge-shaped peripheral ground glass and cavitary opacities consistent with
pulmonary infarcts.
Fig. 3. Repeat Computed Tomography of the chest showing right lower lobe consolidation with small right pleural eﬀusion, right upper lobe consolidation with
partial ground glass opacity and a right upper lobe cavitary lesion measuring 3.5× 2 cm.
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